Will freedom to research and innovate be restricted as the induced pluripotent stem cell field advances toward the clinic, or are concerns premature within a rapidly changing ecosystem?
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bubela, T., FitzGerald G.A. & Gold, E.R. Sci. Transl. Med. 4, 133cm3 (2012).
Bergman, K. & Graff, G. Nat. Biotechnol. 25, 419–424 (2007).
Winickoff, D.E., Krishanu, S. & Graff, G.D. Yale J. Health Policy Law Ethics 9, 52–157 (2009).
Mathews, D.J.H. et al. Science 331, 725–727 (2011).
Schwartz, S.D. et al. Lancet 379, 713–720 (2012).
Takahashi, K. et al. Cell 131, 861–872 (2007).
Yu, J. et al. Science 318, 1917–1920 (2007).
Mathews, D.J.H., Cook-Deegan, R. & Bubela, T. Cell Stem Cell 12, 508–512 (2013).
The Hinxton Group. Consensus statement on policies and practices governing data and materials sharing and intellectual property in stem cell science. (The Hinxton Group, 2010).
Rao, M.S. Stem Cell Res. Ther. 4, 98 (2013).
Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).
BioInformant Worldwide. Complete 2012–13 induced pluripotent stem cell industry report (BioInformant Worldwide, LLC, 2014).
Cyranoski, D. Nat. Med. 19, 510 (2013).
United States of America v. Regenerative Sciences, A Corporation, LLC et al. No. 12–5254, United States Court of Appeals for the District of Columbia Circuit, 4 February 2014.
UK Intellectual Property Office Patent Informatics Team. Stem cells: the UKSCN patent watch landscape (Intellectual Property Office, Newport, UK, 2012).
Hou, P. et al. Science 341, 651–654 (2013).
Feldman, R. & Furth, D. Stanford J. Law Sci. Pol. 3, 17–34 (2010).
Simon, B.M., Murdoch, C.E. & Scott, C.T. Nat. Biotechnol. 28, 557–559 (2010).
Japan Patent No. 2008–131577, 2008; UK Patent No. GB2450603, 2010; US Patent No. 7,682,828, 2010; US Patent Application Patent No. 12/703,015, 2010; US Patent Application Patent No. 12/703,015, 2010.
International Stem Cell Corporation v. Comptroller General of Patents, Patents Court, London, UK, Case No.  EWHC 807 (Ch.); Referral Case C-364/13 (Court of Justice of the European Union, 17 April 2013).
Consumer Watchdog v. Wisconsin Alumni Research Foundation (Fed. Cir. 2013).
House of Commons Science and Technology Committee. Bridging the valley of death: improving the commercialisation of research. Eighth report of session 2012–13 (Report no. HC 348) (House of Commons Stationery Office Limited, London, 2013).
Moran, N. Nat. Biotechnol. 31, 376 (2013).
Initial public offering, filed with the Securities and Exchange Commission, Washington DC, on 3 June 2013, Registration no. 333.
Webb, S. Nat. Biotechnol. 27, 977–979 (2009).
The authors thank B. Larner, F. Wattler and J. Evans (Thomson Reuters) for their invaluable assistance; A. Carr (University of Oxford) and J. Karp (Harvard University and Brigham and Women's Hospital) for their invaluable support and insights; and R. Barker (the Centre for the Advancement of Sustainable Medical Innovation (CASMI)) and M. Morys (CASMI) for their support of the CASMI Translational Stem Cell Consortium. The authors wish to express sincere thanks to the following organizations that have contributed to the consortium as funding and events partners: Centre for the Commercialization of Regenerative Medicine; Celgene Cellular Therapeutics; Cell Therapy Catapult; CIRM; Eisai; GE Healthcare; Lonza; SENS Research Foundation; TAP Biosystems (now Sartorius Stedim); MEDIPOST Co., Ltd.; MEDIPOST America Inc.; the New York Stem Cell Foundation and the US National Institutes of Health Center for Regenerative Medicine. Additionally, CASMI is a past recipient of funding from the UK Technology Strategy Board to support an investigation into cell therapy regulation. The content outlined herein represents the individual opinions of the authors and may not necessarily represent the viewpoints of their employers. D.B. is subject to the CFA Institute's codes, standards and guidelines and as such, must stress that this piece is provided for academic interest only and must not be construed in any way as an investment recommendation.
D.A.B. is a stockholder in Translation Ventures Ltd., which provides cell therapy biomanufacturing, regulatory and financial advice to clients in the cell therapy sector. At the time of publication, D.A.B. and the organizations with which he is affiliated may or may not have agreed and/or pending funding commitments from the organizations named herein. D.A.B. has also consulted for Lonza Group and Sartorius Stedim within the past seven years with a cumulative compensation value greater than $10,000.
About this article
Cite this article
Roberts, M., Wall, I., Bingham, I. et al. The global intellectual property landscape of induced pluripotent stem cell technologies. Nat Biotechnol 32, 742–748 (2014). https://doi.org/10.1038/nbt.2975